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Abstract
Background: The new CoreValve Evolut R has an improved design to minimize paravalvular leak-
age and allows repositioning of the valve. For patients with degenerated bioprosthetic aortic valves, 
transcatheter aortic valve implantation (TAVI) represents a less invasive option. Herein reported are 
valve-in-valve (ViV) implantations of this new valve. 
Methods: A total of 26 patients (mean age 79.4 ± 6.1 years, 17 males and 9 females) were treated 
for severe prosthesis stenosis (n = 9), severe regurgitation (n = 8) or severe combination of stenosis 
and regurgitation (n = 9). All patients underwent transthoracic echocardiography before and after ViV 
implantation. 
Results: Valve-in-valve implantation of a CoreValve Evolut R was performed successfully in all pa-
tients. The mean transaortic gradient for stenotic valves determined by transthoracic echocardiography 
was reduced significantly from 37.5 ± 15.3 mmHg in patients with prosthesis stenosis to 16.3 ± 8.2 
mmHg (p < 0.001). In all cases with severe prosthesis regurgitation, regurgitation was reduced to none 
or mild. All-cause mortality after 30 days was 0%. 
Conclusions: It was concluded that CoreValve Evolut R is well suited for ViV implantation. (Cardiol 
J 2018; 25, 3: 301–307)
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Introduction
For patients with a degenerated bioprosthetic 
heart valve, transcatheter aortic valve implanta-
tion (TAVI) is a less invasive treatment option. 
A reoperation of these mostly elderly patients 
with frequent comorbidities is associated with 
a higher perioperative mortality [1]. Some experi-
ence with valve-in-valve (ViV) implantation of the 
balloon-expandable Edwards Sapien XT valve and 
the self-expandable Medtronic CoreValve system 
has already been published [2, 3]. However, data 
on the new Medtronic CoreValve Evolut R valve 
is scarce [4, 5]. 
The new Medtronic CoreValve Evolut R has 
an improved design to minimize paravalvular leak-
age. In addition, its new delivery system allows for 
repositioning of the valve [6]. Herein are reported 
26 cases of degenerated aortic bioprostheses man-
aged with CoreValve Evolut R. 
Methods
Since 2009, more than 1700 patients under-
went TAVI in the documented center. From April 
2013 to October 2017, 26 patients were treated 
for a failing surgical aortic valve with a CoreVave 
Evolut R. All patients presented with severe co-
morbidities preferring an interventional approach 
as determined by an interdisciplinary heart team 
(Table 1). In all patients, transesophageal echo-
cardiography was performed to determine valve 
pathology prior to the procedure. The aortic an-
nulus diameter was measured in the mid-esopha-
geal long-axis view and/or by computed tomogra-
phy. In all cases a transfemoral access was used. 
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A clinical examination, an electrocardiography and 
a transthoracic echocardiography were performed 
before TAVI and before discharge. 
TAVI was performed in a specially equipped 
hybrid suite under general anesthesia by an in-
terdisciplinary heart team consisting of a cardiac 
surgeon, a cardiologist and an anesthesiologist. All 
relevant baseline, procedural, and follow-up data 
were collected retrospectively. 
A total of 26 patients (mean age 79.4 ± 6.1 
years, 17 male and 9 female) were treated for 
degenerated aortic prosthesis following surgical 
aortic valve replacement. The exact type of sur-
gical bioprosthesis are listed in Table 2. Severe 
aortic stenosis was defined as an effective aortic 
orifice area (EOA) < 1 cm2. 7 prostheses showed 
a high-grade stenosis, 7 prostheses had severe 
aortic regurgitation and 7 showed high grade ste-
nosis combined with serve aortic regurgitation. 
The elevated surgical risk is underscored by the 
STS score for risk of mortality (6.2 ± 3.0%) and 
EuroScore II (17.3 ± 10.5%). All patients were 
analyzed for 30 day survival.
Statistical analysis
Wilcoxon matched pairs signed rank test for 
statistical significance (GraphPad Prism 6, La Jolla, 
CA, USA) was performed. A p-value < 0.05 was 
considered to be statistically significant. When 
appropriate, data are presented as box plots with 
the boundaries of the box as the 75th and 25th per-
centiles, and with a line in the box indicating the 
median. Whiskers above and below the box mark 
maximum and minimum values, respectively.
Compliance with ethical standards
All procedures performed in studies involv-
ing human participants were in accordance with 
the ethical standards of the institutional and/or 
national research committee and with the 1964 
Helsinki declaration and its later amendments or 
comparable ethical standards.
Results
The ViV implantation of the CoreValve Evolut R 
was performed successfully in all patients. In 18 pa- 
tients, an Evolut 23 mm was used, 5 patients re-
ceived an Evolut 26 mm, 2 patients received an 
Evolut 29 mm and 1 patient received an Evolut 
34 mm. The mean transaortic gradient determined 
by transthoracic echocardiography was reduced sig-
nificantly from 37.5 ± 15.3 mmHg in patients with 
prosthetic stenosis to 16.3 ± 8.2 mmHg (p < 0.001) Ta
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(Fig. 1). The EOA increased from 0.8 ± 0.2 cm2 in 
patients with prosthesis stenosis to 1.5 ± 0.4 cm2 
(p < 0.001) (Fig. 2). In all cases with severe aortic 
regurgitation, the regurgitation was reduced to 
none or mild regurgitation. There was no case 
of moderate or severe regurgitation after ViV. In 
3 patients, a postdilatation was performed due to 
excessive calcification. The mean EOA was 1.4 ± 
± 0.4 cm2 for the 23 mm Evolut valve that was 
used the most.
In 3 patients, implantation of a permanent 
pacemaker was necessary. In 2 patients (No. 9 and 
No. 21) pacemaker implantation was necessary due 
to a complete atrioventricular block after TAVI. In 
these cases, the CoreValve Evolut R had to be im-
planted deep into the left ventricular outflow tract 
to avoid obstruction of the right coronary artery for 
patient 9 and to cover a paravalvular regurgitation 
in patient No. 21. In 1 patient, the pacemaker was 
implanted due to symptomatic sick sinus syndrome 
6 days after ViV. In all other cases, no new conduc-
tion disturbances were observed. 
In patient No. 5, the CoreValve Evolut R dis-
located into the ascending aorta after deployment. 
A second CoreValve Evolut R was implanted into 
the surgical valve fixating the first valve in the 
ascending aorta without obstruction of the brachio-
cephalic artery. In this patient, a reduction of the 
mean transaortic gradient was not accomplished. 
In 4 patients (No. 7, 11, 16 and 26), the transaor-
tic gradient was not reduced or even increased 
slightly. In these patients a combination of stenosis 
and regurgitation was an indication for ViV. The 
regurgitation was reduced effectively in all patients. 
In these patients, a short acceleration time of the 
transaortic outflow (< 100 ms) was measured before 
TAVI suggesting a prosthesis-patient mismatch in 
addition to valve degeneration as the reason for el-
evated gradients. Since all patients were considered 
unfit for surgery, the interdisciplinary heart team 
recommended TAVI to reduce regurgitation.
Further complications included 2 strokes in 
patients No. 21 and No. 18. In both patients neu-
rological symptoms regressed spontaneously. 
In patient No. 18, periprocedural obstruction 
of the left coronary artery had to be treated with 
by stent implantation in the left main stem.
All patients were discharged after an average 
postoperative stay of 10 ± 8 days. All-cause mor-
tality after 30 days was 0%.
Discussion
Trancatheter ViV implantation for failing surgi-
cal aortic valves represents an advantageous option 
for high risk patients. The CoreValve Evolut R 
is a new generation valve with approval for ViV 
implantation. 
Insufficient reduction of the transaortic gra-
dients after TAVI is a major problem for ViV im-
plantations in small surgical valves — especially 
in patients with prosthesis-patient mismatch [7]. 
Accordingly, 4 patients in this study with prosthe-
sis-patient mismatch, transaortic gradient could 
not be improved significantly. In these patients, 
however, the indication for ViV was a mix of aortic 
Figure 1. Mean pressure gradients at baseline and after 
valve-in-valve transcatheter aortic valve implantation 
(TAVI) (p < 0.001).
Figure 2. Effective orifice area at baseline and after 
valve-in-valve transcatheter aortic valve implantation 
(TAVI) (p < 0.001).
A B C
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valve disease with predominant aortic regurgita-
tion which was sufficiently reduced. Neverthe-
less, ViV implantations in patients with suspected 
prosthesis-patient mismatch should be reserved 
for patients with very high operative risk. The 
rate of insufficient reduction of the transaortic 
gradient was 19% and therefore comparable with 
the rate for postprocedural elevated gradients in 
small valves of 23.4% for a previous generation of 
self-expanding valves [8].
Moderate or severe paravalvular regurgita-
tions were not observed in any cases. While clearly 
limited by the low number of patients included, 
the present data suggests that the new CoreValve 
Evolut R is suited for successful interventional 
treatment of degenerated surgical prosthetic 
valves. This is an improvement over data for the 
older generation of self-expanding valves with 
a rate for at least moderate regurgitation of 8.9% [8].
Despite the high EuroScore II and STS score 
no patient died within 30 day follow-up.
According to the available literature, ViV im-
plantations are associated with a lower incidence 
of relevant conduction disturbances — most likely 
due to the ability of rigid rings of stented surgical 
valves which prevent pressure load on the atrio-
ventricular conduction system during TAVI [7]. 
In 2 patients, complete atrioventicular block oc-
curred after ViV and permanent pacemaker im-
plantation was performed. Notably, a stentless 
Baxter Prima 25 mm was the degenerated surgical 
valve in 1 patient and a very deep implantation of 
Evolut was necessary to avoid obstruction of the 
right coronary artery. In the other patient, again 
a stentless Elan 27 mm valve was the degenerated 
surgical valve and a very deep implantation of the 
Evolut R was necessary to cover paravalvular 
regurgitation. Both factors likely contributed to 
heart block in our patients as we have previously 
shown that deeper implantation is associated with 
higher risk for permanent pacemaker implantation 
in patients receiving an Edwards Sapien 3 [9]. 
The third pacemaker was implanted due to, most 
likely preexisting, sick sinus syndrome. This rate 
is comparable to the rate of permanent pacemaker 
implantation after ViV procedure with previous 
generations of self-expanding valves [8].
In one other patient, the ViV implantation did 
not reduce the transaortic gradient. In this patient, 
a first CoreValve Evolut R dislocated into the 
ascending aorta after supraannular implantation. 
A second valve was placed intraannularly and thereby 
both replaced the degenerated aortic prosthesis 
and fixated the first valve. In addition, in this patient 
the surgical valve was a 19 mm Carpentier aortic 
valve. In preoperative computed tomography-scan, 
an internal diameter of 18 mm was measured. 
The combination of a small surgical valve and the 
necessity of two transfemoral valves probably 
resulted in an unchanged gradient over the aortic 
valve. This result is comparable with the literature 
for the previous generation of self-expanding ViV 
procedures with a rate which required a second 
valve of 7.5% [8].
In general, current literature suggests that an 
intraanular placement of the valve may result in 
residual stenosis due to incomplete expansion and 
leaflet distortion. Accordingly, a supraannular place-
ment of the valve in ViV implantations should be 
performed to optimize EOA as shown in Figure 3 [10].
Figure 3. Examples of valve-in-valve implantations in patients with different surgical bioprostheses; A. Hancock; 
B. Carpentier; C. MitroFlow.
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Conclusions
It is concluded that the CoreValve Evolut R is 
well suited for ViV implantation. In patients with 
high surgical risk, transcatheter ViV implantation 
represents a beneficial option with low periproce-
dural complications. Promising early results should 
be confirmed by a larger series with long-term 
follow up. 
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